Clinical expert consensus on application of topical growth factors in chronic wounds (2025 edition)
-
摘要: 慢性创面是指经过规范系统治疗,而未能在一定预期时间内实现组织结构完全修复的创面,其具有发病率高、机制复杂、病程迁延、治疗难度大的特点。外用生长因子类药物或生物制剂具有调控细胞增殖、迁移和分化等作用,可有效促进创面愈合进程,已被广泛应用于各类急、慢性创面的修复中。但在各类慢性创面治疗的临床实践中,对于外用生长因子类制剂的应用策略尚存在较多争议。因此,中华医学会烧伤外科学分会、《中华烧伤与创面修复杂志》编辑委员会共同发起并组织多学科专家,基于目前的循证医学证据、临床实践和其他学科临床指南,制订该临床专家共识,旨在进一步规范外用生长因子类制剂在慢性创面临床治疗中的应用。Abstract: Chronic wounds refer to wounds that fail to achieve complete structural repair within the expected time frame despite standardized systemic treatment, which are characterized by high incidence, complex mechanisms, prolonged clinical course, and difficulty in treatment. Topical growth factor drugs or biological agents, which regulate cell proliferation, migration, and differentiation, thereby effectively promoting the wound healing process, are widely used in the repair of various acute and chronic wounds. However, there is still some controversy over the application of topical growth factors in the clinical practice of treating various chronic wounds. Chinese Burn Association and Editorial Committee of Chinese Journal of Burns and Wounds jointly initiated and organized a multidisciplinary expert group. Based on current evidence-based medical evidence, clinical practice, and authoritative guidelines from other disciplines, this clinical expert consensus was developed for further standardization of the application of topical growth factors in the clinical treatment of chronic wounds.
-
Key words:
- Wound healing /
- Therapeutic uses /
- Growth factors /
- Chronic wounds /
- Expert consensus
-
参考文献
(128) [1] 谭谦, 徐晔. 慢性创面治疗的理论和策略[J]. 中华烧伤杂志, 2020, 36(9): 798-802. DOI: 10.3760/cma.j.cn501120-20200728-00361. [2] 陈鏖宇, 王一兵. 慢性创面的病因及发病机制的研究进展[J]. 临床医学进展, 2023, 13(3): 2958-2966. DOI: 10.12677/acm.2023.133419. [3] FalangaV, IsseroffRR, SoulikaAM, et al. Chronic wounds[J]. Nat Rev Dis Primers, 2022,8(1):50. DOI: 10.1038/s41572-022-00377-3. [4] 孙晓芳, 谢挺. 创面修复中生长因子研究及临床干预新进展[J]. 创伤外科杂志, 2016, 18(3): 190-193. DOI: 10.3969/j.issn.1009-4237.2016.03.023. [5] ThammOC, TheodorouP, StuermerE, et al. Adipose-derived stem cells and keratinocytes in a chronic wound cell culture model: the role of hydroxyectoine[J]. Int Wound J, 2015,12(4):387-396. DOI: 10.1111/iwj.12120. [6] HanCM, ChengB, WuP, et al. Clinical guideline on topical growth factors for skin wounds[J/OL]. Burns Trauma, 2020,8:tkaa035[2025-04-26]. https://pubmed.ncbi.nlm.nih.gov/33015207/. DOI: 10.1093/burnst/tkaa035. [7] 中华医学会烧伤外科学分会, 《中华烧伤杂志》编辑委员会. 皮肤创面外用生长因子的临床指南[J]. 中华烧伤杂志, 2017, 33(12): 721-727. DOI: 10.3760/cma.j.issn.1009-2587.2017.12.001. [8] 中国老年医学学会烧创伤分会. 浓缩血小板制品在创面修复中应用的全国专家共识(2020版)[J]. 中华烧伤杂志, 2020, 36(11): 993-1002. DOI: 10.3760/cma.j.cn501120-20200507-00256. [9] MortonLM, PhillipsTJ. Wound healing and treating wounds: differential diagnosis and evaluation of chronic wounds[J]. J Am Acad Dermatol, 2016,74(4):589-605; quiz 605-606. DOI: 10.1016/j.jaad.2015.08.068. [10] HillerJ, StratmannB, TimmJ, et al. Enhanced growth factor expression in chronic diabetic wounds treated by cold atmospheric plasma[J]. Diabet Med, 2022, 39(6): e14787. DOI: 10.1111/dme.14787. [11] BiQ, ZhangQ, MaJ, et al. Effect of combination therapy with alginate dressing and mouse epidermal growth factor on epidermal stem cells in patients with refractory wounds[J]. Chin Med J (Engl), 2012, 125(2): 257-261. DOI: 10.3760/cma.j.issn.0366-6999.2012.02.018. [12] FangY, ShenJ, YaoM, et al. Granulocyte-macrophage colony-stimulating factor enhances wound healing in diabetes via upregulation of proinflammatory cytokines[J]. Br J Dermatol, 2010,162(3):478-486. DOI: 10.1111/j.1365-2133.2009.09528.x. [13] GohelMS, WindhaberRA, TarltonJF, et al. The relationship between cytokine concentrations and wound healing in chronic venous ulceration[J]. J Vasc Surg, 2008,48(5):1272-1277. DOI: 10.1016/j.jvs.2008.06.042. [14] StaceyM. Combined topical growth factor and protease inhibitor in chronic wound healing: protocol for a randomized controlled proof-of-concept study[J]. JMIR Res Protoc, 2018,7(4):e97. DOI: 10.2196/resprot.8327. [15] HurlowJ, WolcottRD, BowlerPG. Clinical management of chronic wound infections: the battle against biofilm[J]. Wound Repair Regen, 2025,33(1):e13241. DOI: 10.1111/wrr.13241. [16] BeidlerSK, DouilletCD, BerndtDF, et al. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy[J]. J Vasc Surg, 2009,49(4):1013-1020. DOI: 10.1016/j.jvs.2008.11.049. [17] SmartH, SibbaldRG, GoodmanL, et al. Wound bed preparation 2024: Delphi consensus on foot ulcer management in resource-Limited settings[J]. Adv Skin Wound Care, 2024,37(4):180-196. DOI: 10.1097/ASW.0000000000000120. [18] 中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 糖尿病足溃疡创面治疗专家共识(2024)[J]. 中华内分泌代谢杂志, 2024, 40(7): 565-569. DOI: 10.3760/cma.j.cn311282-20240625-00281. [19] 李怡桐, 孙艳艳, 乔绍俊, 等. 消毒剂对重组Ⅲ型人源化胶原蛋白促细胞黏附活性的影响[J]. 日用化学工业(中英文), 2023, 53(7): 789-795. DOI: 10.3969/j.issn.2097-2806.2023.07.008. [20] 高兴新, 王润秀, 林源, 等. 外用消毒剂对重组人表皮细胞生长因子促烧伤残余创面愈合作用的影响[J].广西医学,2008,30(6):884-885. DOI: 10.3969/j.issn.0253-4304.2008.06.052. [21] 常涛. 银离子消毒剂研究概述[J]. 解放军预防医学杂志, 2005,23(1): 75-77. DOI: 10.3969/j.issn.1001-5248.2005.01.031. [22] 刘胜杰, 马武秀, 陈聪聪, 等. 富血小板血浆及其复合银离子的体外抑菌效果研究[J]. 安徽医学, 2023, 44(11): 1329-1333. DOI: 10.3969/j.issn.1000-0399.2023.11.011. [23] ParkKH, HanSH, HongJP, et al. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: a phase III multicenter, double-blind, randomized, placebo-controlled trial[J]. Diabetes Res Clin Pract, 2018,142:335-344. DOI: 10.1016/j.diabres.2018.06.002. [24] OliveiraBC, deOliveira BGRB, DeutschG, et al. Effectiveness of a synthetic human recombinant epidermal growth factor in diabetic patients wound healing: pilot, double-blind, randomized clinical controlled trial[J]. Wound Repair Regen, 2021,29(6):920-926. DOI: 10.1111/wrr.12969. [25] ViswanathanV, JuttadaU, BabuM. Efficacy of recombinant human epidermal growth factor (Regen-D 150) in healing diabetic foot ulcers: a hospital-based randomized controlled trial[J]. Int J Low Extrem Wounds, 2020,19(2):158-164. DOI: 10.1177/1534734619892791. [26] ThanigaimaniS, JinH, AhmadU, et al. Comparative efficacy of growth factor therapy in healing diabetes-related foot ulcers: a network meta-analysis of randomized controlled trials[J]. Diabetes Metab Res Rev, 2023,39(5):e3670. DOI: 10.1002/dmrr.3670. [27] WongAYW, HooiNMF, YeoBSY, et al. Improving diabetic wound-healing outcomes with topical growth factor therapies[J]. J Clin Endocrinol Metab, 2024,109(8):e1642-e1651. DOI: 10.1210/clinem/dgae128. [28] ZhaoDY, SuYN, LiYH, et al. Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: a systematic review and meta-analysis of randomised controlled trials[J]. Int Wound J, 2020,17(4):1062-1073. DOI: 10.1111/iwj.13377. [29] Malekpour AlamdariN, ShafieeA, MirmohseniA, et al. Evaluation of the efficacy of platelet-rich plasma on healing of clean diabetic foot ulcers: a randomized clinical trial in Tehran, Iran[J]. Diabetes Metab Syndr, 2021,15(2):621-626. DOI: 10.1016/j.dsx.2021.03.005. [30] ElsaidA, El-SaidM, EmileS, et al. Randomized controlled trial on autologous platelet-rich plasma versus saline dressing in treatment of non-healing diabetic foot ulcers[J]. World J Surg, 2020,44(4):1294-1301. DOI: 10.1007/s00268-019-05316-0. [31] LiL, ChenD, WangC, et al. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: a prospective, randomized clinical trial[J]. Wound Repair Regen, 2015,23(4):495-505. DOI: 10.1111/wrr.12294. [32] LiY, GaoY, GaoY, et al. Autologous platelet-rich gel treatment for diabetic chronic cutaneous ulcers: a meta-analysis of randomized controlled trials[J]. J Diabetes, 2019,11(5):359-369. DOI: 10.1111/1753-0407.12850. [33] RainysD, CepasA, DambrauskaiteK, et al. Effectiveness of autologous platelet-rich plasma gel in the treatment of hard-to-heal leg ulcers: a randomised control trial[J]. J Wound Care, 2019,28(10):658-667. DOI: 10.12968/jowc.2019.28.10.658. [34] UCHIH, IGARASHIA, URABEK, et al. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer[J]. Eur J Dermatol, 2009, 19(5): 461-468. DOI: 10.1684/ejd.2009.0750. [35] RichardJL, Parer-RichardC, DauresJP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study[J]. Diabetes Care, 1995,18(1):64-69. DOI: 10.2337/diacare.18.1.64. [36] 王华鑫, 苏智铿, 陈小青, 等. 重组牛碱性成纤维细胞生长因子在老年糖尿病足溃疡患者中的应用[J]. 深圳中西医结合杂志, 2021, 31(15): 146-147. DOI: 10.16458/j.cnki.1007-0893.2021.15.068. [37] 李冰玉. 重组牛碱性成纤维细胞生长因子在老年糖尿病足患者溃疡中的应用效果及护理[J]. 中国卫生标准管理, 2016, 7(6): 224-225. DOI: 10.3969/j.issn.1674-9316.2016.06.167. [38] ShengX, HuL, LiT, et al. Clinical efficacy and mechanism of the combination of autologous platelet-rich gel and recombinant human acidic fibroblast growth factor in the management of refractory diabetic foot[J]. Front Endocrinol (Lausanne), 2024,15:1374507. DOI: 10.3389/fendo.2024.1374507. [39] 李军, 张莉莉, 张凤新. 重组人酸性成纤维细胞生长因子促进慢性溃疡性创面愈合的临床研究[J]. 中国医药导报, 2014, 11(31): 49-51,60. [40] XuJ, MinD, GuoG, et al. Experimental study of epidermal growth factor and acidic fibroblast growth factor in the treatment of diabetic foot wounds[J]. Exp Ther Med, 2018,15(6):5365-5370. DOI: 10.3892/etm.2018.6131. [41] MaC, HernandezMA, KirkpatrickVE, et al. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial[J]. Wounds, 2015,27(4):83-91. [42] WaycasterCR, GilliganAM, MotleyTA. Cost-effectiveness of becaplermin gel on diabetic foot ulcer healing changes in wound surface area[J]. J Am Podiatr Med Assoc, 2016,106(4):273-282. DOI: 10.7547/15-004. [43] PerssonU, WillisM, OdegaardK, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data[J]. Value Health, 2000,3Suppl 1:S39-46. DOI: 10.1046/j.1524-4733.2000.36027.x. [44] 姜丽娜. 重组人粒细胞巨噬细胞集落刺激因子治疗糖尿病足的临床疗效及安全性评价[J].航空航天医学杂志,2016,27(9):1126-1127. DOI: 10.3969/j.issn.2095-1434.2016.09.030. [45] BianchiL, GinebriA, HagmanJH, et al. Local treatment of chronic cutaneous leg ulcers with recombinant human granulocyte-macrophage colony-stimulating factor[J]. J Eur Acad Dermatol Venereol, 2002,16(6):595-598. DOI: 10.1046/j.1468-3083.2002.00526.x. [46] CianfaraniF, TommasiR, FaillaCM, et al. Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed[J]. Br J Dermatol, 2006,154(1):34-41. DOI: 10.1111/j.1365-2133.2005.06925.x. [47] ChenP, VilorioNC, DhatariyaK, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update)[J]. Diabetes Metab Res Rev, 2024,40(3):e3644. DOI: 10.1002/dmrr.3644. [48] Da CostaRM, Ribeiro JesusFM, AnicetoC, et al. Randomized, double-blind, placebo-controlled, dose- ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers[J]. Wound Repair Regen, 1999,7(1):17-25. DOI: 10.1046/j.1524-475x.1999.00017.x. [49] JaschkeE, UmlauftJ, Palmer-ReichelK, et al. Low-dose topical recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) therapy for chronic venous leg ulcers, 10-year follow-up[J]. Dermatologie (Heidelb), 2023,74(1):41-48. DOI: 10.1007/s00105-022-05068-4. [50] ElbarbaryAH, HassanHA, ElbendakEA. Autologous platelet-rich plasma injection enhances healing of chronic venous leg ulcer: a prospective randomised study[J]. Int Wound J, 2020,17(4):992-1001. DOI: 10.1111/iwj.13361. [51] ShehabAW, EleshraA, FoudaE, et al. Randomized prospective comparative study of platelet-rich plasma versus conventional compression in treatment of post-phlebitic venous ulcer[J]. Vascular, 2023,31(6):1222-1229. DOI: 10.1177/17085381221104629. [52] MiłekT, NagrabaŁ, MitekT, et al. Autologous platelet-rich plasma reduces healing time of chronic venous leg ulcers: a prospective observational study[J]. Adv Exp Med Biol, 2019,1176:109-117. DOI: 10.1007/5584_2019_388. [53] 徐强. 富血小板血浆(PRP)治疗慢性下肢静脉曲张性溃疡的早期疗效观察[J]. 医药前沿, 2014(3): 164-165. DOI: 10.3969/j.issn.2095-1752.2014.03.146. [54] 况迎接, 赵筱雯, 冯云霞. 富血小板血浆联合新型敷料治疗下肢静脉溃疡的效果观察[J]. 护理实践与研究, 2017, 14(4): 125-126. DOI: 10.3969/j.issn.1672-9676.2017.04.054. [55] ElgarhyLH, El-AshmawyAA, BedeerAE, et al. Evaluation of safety and efficacy of autologous topical platelet gel vs platelet rich plasma injection in the treatment of venous leg ulcers: a randomized case control study[J]. Dermatol Ther, 2020, 33(6): e13897. DOI: 10.1111/dth.13897. [56] 余静雅, 石玉兰, 戴燕, 等. 富血小板血浆治疗下肢静脉溃疡疗效及安全性的Meta分析[J]. 血管与腔内血管外科杂志, 2023, 9(6): 645-653. DOI: 10.19418/j.cnki.issn2096-0646.2023.06.02. [57] LeeY, LeeMH, PhillipsSA, et al. Growth factors for treating chronic venous leg ulcers: a systematic review and meta-analysis[J]. Wound Repair Regen, 2022,30(1):117-125. DOI: 10.1111/wrr.12982. [58] FalangaV, EaglsteinWH, BucaloB, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers[J]. J Dermatol Surg Oncol, 1992,18(7):604-606. DOI: 10.1111/j.1524-4725.1992.tb03514.x. [59] 肖榕婵, 熊想莲, 吴贞华. 重组人表皮生长因子对下肢静脉性溃疡的疗效观察[J]. 中国现代药物应用, 2022, 16(9): 150-152. DOI: 10.14164/j.cnki.cn11-5581/r.2022.09.052. [60] 江榕, 何洪青, 陈小彬, 等. 大隐静脉高位结扎联合泡沫硬化剂注射术+外用重组人酸性成纤维细胞生长因子治疗重度静脉曲张合并溃疡患者的临床疗效[J]. 血管与腔内血管外科杂志, 2024, 10(3): 257-261,281. DOI: 10.19418/j.cnki.issn2096-0646.2024.03.01. [61] 中国微循环学会周围血管疾病专业委员会. 下肢静脉性溃疡伤口管理专家共识[J]. 血管与腔内血管外科杂志, 2023, 9(1): 1-6,19. DOI: 10.19418/j.cnki.issn2096-0646.2023.01.01. [62] ValeskyEM, Hach-WunderleV, ProtzK, et al. Diagnosis and treatment of venous leg ulcers: S2k Guideline of the German Society of Phlebology and Lymphology (DGPL) e.V[J]. J Dtsch Dermatol Ges, 2024,22(7):1039-1051. DOI: 10.1111/ddg.15415. [63] GeMW, HuFH, JiaYJ, et al. Efficacy of recombinant human epidermal growth factor in pressure injury healing: evidence from Chinese randomized controlled trials[J]. Wound Manag Prev, 2024,70(1).DOI: 10.25270/wmp.22092. [64] 张乐乐, 战青, 宋旭林, 等. 重组人表皮生长因子治疗压力性损伤疗效的系统评价[J]. 上海护理, 2022, 22(7): 44-49. DOI: 10.3969/j.issn.1009-8399.2022.07.011. [65] 吴文娜. 重组人表皮生长因子联合磺胺嘧啶银乳膏治疗压力性损伤的疗效分析[J]. 中国卫生标准管理, 2022, 13(17): 153-157. DOI: 10.3969/j.issn.1674-9316.2022.17.033. [66] 裴秋艳, 王平, 李志刚, 等. 表皮生长因子联合银离子敷料对Ⅲ期、Ⅳ期压力性损伤患者血清炎性细胞因子和临床疗效的影响[J]. 四川医学, 2022, 43(1): 63-66. DOI: 10.16252/j.cnki.issn1004-0501-2022.01.013. [67] RobsonMC, HillDP, SmithPD, et al. Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response[J]. Ann Surg, 2000,231(4):600-611. DOI: 10.1097/00000658-200004000-00020. [68] 张诚, 杨金存, 冯永强, 等. 联合bFGF的负压创面治疗技术在难治性压力性溃疡治疗中的应用[J]. 中华医学杂志, 2012, 92(40): 2862-2864. DOI: 10.3760/cma.j.issn.0376-2491.2012.40.016. [69] UçarÖ, ÇelikS. Comparison of platelet-rich plasma gel in the care of the pressure ulcers with the dressing with serum physiology in terms of healing process and dressing costs[J]. Int Wound J, 2020,17(3):831-841. DOI: 10.1111/iwj.13344. [70] Ramos-TorrecillasJ, García-MartínezO, De Luna-BertosE, et al. Effectiveness of platelet-rich plasma and hyaluronic acid for the treatment and care of pressure ulcers[J]. Biol Res Nurs, 2015,17(2):152-158. DOI: 10.1177/1099800414535840. [71] TianB, YangX, LiuY, et al. The application effect of autologous platelet-rich plasma combined with negative pressure sealing drainage technology in pressure ulcer wound repair[J]. Medicine (Baltimore), 2024,103(44):e39672. DOI: 10.1097/MD.0000000000039672. [72] 安林静, 侯月丽, 张兵, 等. 富血小板血浆技术联合伤口治疗师主导的综合管理在骨科住院老年患者压力性损伤中的应用[J]. 老年医学与保健, 2024, 30(3): 830-833,839. DOI: 10.3969/j.issn.1008-8296.2024.03.048. [73] 杨柳, 张友群, 刘娟娟, 等. 重组人粒细胞巨噬细胞集落刺激因子在压疮护理中的应用[J].中国美容医学, 2014, 23(4): 332-335. DOI: 10.15909/j.cnki.cn61-1347/r.2014.04.004. [74] 王湘, 石海燕. 重组人粒细胞巨噬细胞集落刺激因子治疗老年患者气管插管致鼻压疮的效果观察[J]. 天津护理, 2017, 25(3): 223-224. DOI: 10.3969/j.issn.1006-9143.2017.03.013. [75] GilliganAM, WaycasterCR, MilneCT. Cost effectiveness of becaplermin gel on wound closure for the treatment of pressure injuries[J]. Wounds, 2018, 30(6): 197-204. DOI: 10.1111/wrr.12285. [76] KallianinenLK, HirshbergJ, MarchantB, et al. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers[J]. Plast Reconstr Surg, 2000,106(6):1243-1248. DOI: 10.1097/00006534-200011000-00001. [77] ReesRS, RobsonMC, SmiellJM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study[J]. Wound Repair Regen, 1999,7(3):141-147. DOI: 10.1046/j.1524-475x.1999.00141.x. [78] GouldLJ, AlderdenJ, AslamR, et al. WHS guidelines for the treatment of pressure ulcers-2023 update[J]. Wound Repair Regen, 2024,32(1):6-33. DOI: 10.1111/wrr.13130. [79] KottnerJ, CuddiganJ, CarvilleK, et al. Prevention and treatment of pressure ulcers/injuries: the protocol for the second update of the international Clinical Practice Guideline 2019[J]. J Tissue Viability, 2019,28(2):51-58. DOI: 10.1016/j.jtv.2019.01.001. [80] 李凤菊, 朱玉霞, 侯堆鹏, 等. 德莫林皮肤创面无机诱导活性敷料联合重组牛碱性成纤维细胞生长因子治疗放射性皮肤损伤的临床效果分析[J]. 中国医药, 2023, 18(10): 1537-1541. DOI: 10.3760/j.issn.1673-4777.2023.10.021. [81] 余艳梅, 韦妹爱, 刘丽琼, 等. 康复新液联合重组牛碱性成纤维细胞生长因子凝胶治疗Ⅱ~Ⅲ级放射性皮炎的效果观察[J]. 中国现代医生, 2021, 59(16): 8-11. [82] 陈辉, 张国安. 碱性成纤维细胞生长因子干粉剂并中药修复放射性溃疡创面愈合18例[J]. 中国组织工程研究与临床康复, 2007, 11(19): 3797-3799. DOI: 10.3321/j.issn:1673-8225.2007.19.040. [83] KongM, HongSE. Topical use of recombinant human epidermal growth factor (EGF)-based cream to prevent radiation dermatitis in breast cancer patients: a single-blind randomized preliminary study[J]. Asian Pac J Cancer Prev, 2013,14(8):4859-4864. DOI: 10.7314/apjcp.2013.14.8.4859. [84] LiuS, WangYL, ShiST, et al. The effect of recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study[J]. BMC Cancer, 2022,22(1):1140. DOI: 10.1186/s12885-022-10226-x. [85] KouvarisJR, KoulouliasVE, PlataniotisGA, et al. Topical granulocyte-macrophage colony-stimulating factor for radiation dermatitis of the vulva[J]. Br J Dermatol, 2001,144(3):646-647. DOI: 10.1046/j.1365-2133.2001.04115.x. [86] 熊锐华, 龚震宇, 田秀荣, 等. 重组人粒细胞巨噬细胞集落刺激因子对鼻咽癌急性放射性皮炎的治疗[J]. 肿瘤, 2015, 35(8): 911-914. DOI: 10.3781/j.issn.1000-7431.2015.44.321. [87] IervolinoV, Di CostanzoG, AzzaroR, et al. Platelet gel in cutaneous radiation dermatitis[J]. Support Care Cancer, 2013,21(1):287-293. DOI: 10.1007/s00520-012-1635-0. [88] CrovettiG, MartinelliG, IssiM, et al. Platelet gel for healing cutaneous chronic wounds[J]. Transfus Apher Sci, 2004,30(2):145-151. DOI: 10.1016/j.transci.2004.01.004. [89] BehroozianT, BonomoP, PatelP, et al. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations[J]. Lancet Oncol, 2023,24(4):e172-e185. DOI: 10.1016/S1470-2045(23)00067-0. [90] 中国老年医学学会烧创伤分会, 中华医学会组织修复与再生分会, 中国康复医学会再生医学与康复专业委员会, 等. 放射性皮肤损伤的诊断和治疗专家共识(2024版)[J]. 中华烧伤与创面修复杂志, 2024, 40(8): 701-712. DOI: 10.3760/cma.j.cn501225-20240126-00033. [91] 范铭, 冯梅, 袁双虎. 放射性皮炎的预防与治疗临床实践指南[J]. 中华肿瘤防治杂志, 2023, 30(6): 315-323. DOI: 10.16073/j.cnki.cjcpt.2023.06.01. [92] TabriziMN, Chams-DavatchiC, EsmaeeliN, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial[J]. J Eur Acad Dermatol Venereol, 2007,21(1):79-84. DOI: 10.1111/j.1468-3083.2006.01873.x. [93] ShpiroD, GilatD, Fisher-FeldL, et al. Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor[J]. Br J Dermatol, 1998,138(2):368-369. DOI: 10.1046/j.1365-2133.1998.02103.x. [94] Braun-FalcoM, StockK, RingJ, et al. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum[J]. Br J Dermatol, 2002,147(4):829-831. DOI: 10.1046/j.1365-2133.2002.495514.x. [95] 王世岭, 邓诗琳, 马建丽, 等. 不同剂型重组人表皮生长因子对烧伤创面促愈合作用比较[J]. 中国临床药理学杂志, 2002, 18(1): 12-14. DOI: 10.3969/j.issn.1001-6821.2002.01.003. [96] 安宏元, 陈杰翔. 重组人表皮生长因子不同剂型作用于糖尿病溃疡动物模型的疗效比较[J]. 中国现代医药杂志, 2010, 12(10): 82-85. DOI: 10.3969/j.issn.1672-9463.2010.10.033. [97] 孙世光, 王建民, 余明莲. 重组人表皮生长因子不同制剂稳定性考察[J].解放军药学学报,2009,25(6):489-491. [98] 李校堃,许华,赵文,等.重组人酸性成纤维细胞生长因子皮肤用药的药代动力学[J]. 药学学报,2002,37(6):424-427.DOI: 10.3321/j.issn:0513-4870.2002.06.007. [99] 姚越苏, 费存恩, 李祖成, 等. 不同剂量重组牛碱性成纤维细胞生长因子治疗创面的比较[J]. 中华烧伤杂志, 2001, 17(1): 10-12. DOI: 10.3760/cma.j.issn.1009-2587.2001.01.003. [100] MorimotoN, YoshimuraK, NiimiM, et al. Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers[J]. Tissue Eng Part A, 2013,19(17/18):1931-1940. DOI: 10.1089/ten.tea.2012.0634. [101] 袁戈恒, 郭晓蕙, 冉兴无, 等. 重组人血小板源生长因子凝胶剂治疗慢性糖尿病足溃疡的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(6): 424-428. DOI: 10.13699/j.cnki.1001-6821.2015.06.008. [102] Fernández-MontequínJI, Valenzuela-SilvaCM, DíazOG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study[J]. Int Wound J, 2009,6(6):432-443. DOI: 10.1111/j.1742-481X.2009.00641.x. [103] YarahmadiA, Saeed ModagheghMH, Mostafavi-PourZ, et al. The effect of platelet-rich plasma-fibrin glue dressing in combination with oral vitamin E and C for treatment of non-healing diabetic foot ulcers: a randomized, double-blind, parallel-group, clinical trial[J]. Expert Opin Biol Ther, 2021,21(5):687-696. DOI: 10.1080/14712598.2021.1897100. [104] 佘雪丽. 重组牛碱性成纤维细胞生长因子联合复方维生素B12治疗鼻咽癌Ⅱ级及以上急性放射性皮炎效果研究[J]. 现代医药卫生, 2019, 35(17): 2638-2639,2642. DOI: 10.3969/j.issn.1009-5519.2019.17.014. [105] 杨德勇, 蔡雪桃, 李洁华, 等. 复方多黏菌素B软膏联合重组人表皮生长因子治疗糖尿病皮肤难愈性溃疡的疗效观察[J]. 吉林医学, 2021, 42(5): 1053-1056. DOI: 10.3969/j.issn.1004-0412.2021.05.010. [106] 潘存梅, 杨颖, 张月芬, 等. 芦荟联合重组人表皮生长因子防治鼻咽癌急性放射性皮炎的疗效观察[J]. 现代肿瘤医学, 2018, 26(2): 194-197. DOI: 10.3969/j.issn.1672-4992.2018.02.009. [107] ZhangK, LiY, HeJ, et al. Therapeutic effect of epidermal growth factor combined with nano silver dressing on diabetic foot patients[J]. Front Pharmacol, 2021,12:627098. DOI: 10.3389/fphar.2021.627098. [108] 郭小媛, 冯毅, 周卫锦. 重组生长因子凝胶联合银离子抗菌敷料在糖尿病足感染控制中的疗效[J].中国高等医学教育,2019(4):136-137. DOI: 10.3969/j.issn.1002-1701.2019.04.072. [109] LeeJ, LeeSW, HongJP, et al. Foam dressing with epidermal growth factor for severe radiation dermatitis in head and neck cancer patients[J]. Int Wound J, 2016,13(3):390-393. DOI: 10.1111/iwj.12317. [110] HongJP, JungHD, KimYW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers[J]. Ann Plast Surg, 2006,56(4):394-398; discussion 399-400. DOI: 10.1097/01.sap.0000198731.12407.0c. [111] 陈千益, 欧敬民, 忻卫平, 等. 重组牛碱性成纤维细胞生长因子联合藻酸盐敷料治疗老年人慢性溃疡创面[J]. 现代医学, 2011, 39(4): 412-416. DOI: 10.3969/j.issn.1671-7562.2011.04.007. [112] MonamiM, RagghiantiB, ScatenaA, et al. Effectiveness of different advanced wound dressings versus standard of care for the management of diabetic foot ulcers: a meta-analysis of randomized controlled trials for the development of the Italian guidelines for the treatment of diabetic foot syndrome[J]. Acta Diabetol, 2024,61(12):1517-1526. DOI: 10.1007/s00592-024-02320-2. [113] 韦礼永, 韦仁杰, 黄大波. PRP局部注射联合局部氧疗治疗Wagner分级2~4级糖尿病足疗效观察[J]. 中国美容医学, 2024, 33(2): 38-41. [114] 张艺, 王思雨, 杨晴, 等. 自体富血小板血浆/凝胶联合负压封闭引流术治疗糖尿病足溃疡的荟萃分析[J]. 生物医学工程与临床, 2024,28(3): 389-397. DOI: 10.13339/j.cnki.sglc.20240422.017. [115] 郭正东, 程飚. 自体富血小板血浆在糖尿病足溃疡的临床应用[J]. 中国医疗美容, 2022, 12(1): 25-28. DOI: 10.19593/j.issn.2095-0721.2022.01.007. [116] 黄春晓, 陈仕新, 谭美华. 重组人酸性成纤维细胞生长因子持续冲洗联合负压引流治疗难愈性皮肤溃疡的效果观察[J]. 中国当代医药, 2015, 22(8): 29-31. [117] 曾婷, 吕晋元, 谭映雪, 等. 封闭式负压引流联合三种不同方法治疗糖尿病足溃疡的疗效分析[J]. 中国医疗美容, 2024, 14(2): 50-53. DOI: 10.19593/j.issn.2095-0721.2024.02.012. [118] HsuJY, ChangJY, ChangKY, et al. Epidermal growth factor-induced pyruvate dehydrogenase kinase 1 expression enhances head and neck squamous cell carcinoma metastasis via up-regulation of fibronectin[J]. FASEB J, 2017,31(10):4265-4276. DOI: 10.1096/fj.201700156R. [119] XuJ, BianL, YouD, et al. PDGF-BB accelerates TSCC via fibroblast lactates limiting miR-26a-5p and boosting mitophagy[J]. Cancer Cell Int, 2024,24(1):5. DOI: 10.1186/s12935-023-03172-6. [120] LinLH, LinJS, YangCC, et al. Overexpression of platelet-derived growth factor and its receptor are correlated with oral tumorigenesis and poor prognosis in oral squamous cell carcinoma[J]. Int J Mol Sci, 2020,21(7):2360.DOI: 10.3390/ijms21072360. [121] LimYJ, JeonSR, KohJM, et al. Tumor growth suppression and enhanced radioresponse by an exogenous epidermal growth factor in mouse xenograft models with A431 cells[J]. Cancer Res Treat, 2015,47(4):921-930. DOI: 10.4143/crt.2014.153. [122] RadererM, KornekG, HejnaM, et al. Topical granulocyte-macrophage colony-stimulating factor in patients with cancer and impaired wound healing[J]. J Natl Cancer Inst, 1997,89(3):263. DOI: 10.1093/jnci/89.3.263. [123] 葛淑宏, 赵启明, 黄春燕, 等. 浓缩生长因子在老年患者创面护理中的应用[J/CD]. 中华老年病研究电子杂志, 2023, 10(4): 36-39. DOI: 10.3877/cma.j.issn.2095-8757.2023.04.006. [124] 刘玉昌, 刘建宁, 李亚洲. 重组人酸性成纤维细胞生长因子促进儿童创面愈合的多中心、开放性随机对照试验[J]. 中国药师, 2015, 18(1): 77-79. DOI: 10.3969/j.issn.1008-049X.2015.01.024. [125] 魏松, 黄志见, 殷炜, 等. 重组人表皮细胞生长因子凝胶联合磺胺嘧啶银在儿童烫伤创面修复中的临床应用[J]. 中国医疗美容, 2023, 13(9): 29-32. DOI: 10.19593/j.issn.2095-0721.2023.09.009. [126] 闫晓华, 邱林. rhGM-CSF及rb-bFGF治疗儿童小面积浅度烧伤创面临床对比研究[J].儿科药学杂志,2013,19(12):11-14. DOI: 10.13407/j.cnki.jpp.1672-108x.2013.12.005. [127] 陈富禄, 黎洪棉, 韩良枢. 自体富血小板血浆凝胶修复儿童面部Ⅱ度烧伤创面[J]. 中国组织工程研究与临床康复, 2011, 15(34): 6453-6456. DOI: 10.3969/j.issn.1673-8225.2011.34.045. [128] 中华医学会烧伤外科学分会. 儿童深Ⅱ度烧伤创面处理专家共识(2023版)[J]. 中华烧伤与创面修复杂志, 2023, 39(10): 901-910. DOI: 10.3760/cma.j.cn501225-20230730-00026. -
图 1 《慢性创面外用生长因子的临床专家共识（2025版）》专家推荐意见流程图
注：EGF为表皮生长因子,bFGF为碱性成纤维细胞生长因子,PRP为富血小板血浆,aFGF为酸性成纤维细胞生长因子,PDGF为血小板源性生长因子,GM-CSF为粒细胞-巨噬细胞集落刺激因子《慢性创面外用生长因子的临床专家共识（2025版）》编写组
Table 1. 2011版牛津大学循证医学中心证据等级标准
证据等级 具体描述 1级 基于随机对照试验或单人交叉临床试验的系统性文献回顾,对随机性研究的系统综述 2级 随机对照试验或效果显著的观察性研究 3级 非随机性、对照性队列研究或随访研究 4级 病例系列、病例对照研究或历史对照研究 5级 基于机制的推论 
下载: 导出CSV
-
下载:
图(1) / 表(1)
计量
- 文章访问数: 699
- HTML全文浏览量: 36
- PDF下载量: 181
- 被引次数: 0
